{"filing":{"accession_number":"0001104659-26-093353","cik":"0001847367","ticker":"ALMS","company_name":"ALUMIS INC.","form":"8-K","filing_date":"2026-08-10","report_date":"2026-08-10","primary_document":"tm2622655d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1847367/000110465926093353/tm2622655d1_8k.htm"},"events":[{"id":26541,"run_id":24125,"accession_number":"0001104659-26-093353","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Alumis disclosed topline results from the ONWARD3 Phase 3 long-term extension study for envudeucitinib, showing 54% PASI 100 skin clearance and a favorable safety profile, with plans to submit an NDA to the FDA in Q4 2026. This is a material clinical milestone for a late-stage biopharmaceutical company's lead candidate, affecting investor assessment of regulatory and commercialization prospects, but does not fit the earnings_release category (which typically applies to financial results) or other specific event types. The disclosure centers on clinical trial progress and regulatory pathway advancement rather than financial results, M\u0026A activity, or governance matters.","company_name":"ALUMIS INC.","ticker":"ALMS","filing_date":"2026-08-10","form":"8-K","submitted_at":null,"items":[{"id":27701,"accession_number":"0001104659-26-093353","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Alumis disclosed topline results from the ONWARD3 Phase 3 long-term extension study for envudeucitinib, showing 54% PASI 100 skin clearance and a favorable safety profile, with plans to submit an NDA to the FDA in Q4 2026. This is a material clinical milestone for a late-stage biopharmaceutical company's lead candidate, affecting investor assessment of regulatory and commercialization prospects, but does not fit the earnings_release category (which typically applies to financial results) or other specific event types. The disclosure centers on clinical trial progress and regulatory pathway advancement rather than financial results, M\u0026A activity, or governance matters.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T20:11:17.077907+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":27701,"accession_number":"0001104659-26-093353","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Alumis disclosed topline results from the ONWARD3 Phase 3 long-term extension study for envudeucitinib, showing 54% PASI 100 skin clearance and a favorable safety profile, with plans to submit an NDA to the FDA in Q4 2026. This is a material clinical milestone for a late-stage biopharmaceutical company's lead candidate, affecting investor assessment of regulatory and commercialization prospects, but does not fit the earnings_release category (which typically applies to financial results) or other specific event types. The disclosure centers on clinical trial progress and regulatory pathway advancement rather than financial results, M\u0026A activity, or governance matters.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T20:11:17.077907+00:00","company_name":"ALUMIS INC.","ticker":"ALMS","filing_date":"2026-08-10"}]}